Categories: News

Aptose to Participate in Two Biotech Events in January 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

H.C. Wainwright BIOCONNECT Virtual Conference —

11th Annual LifeSci Partners Corporate Access Event —

SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners Corporate Access Event. The Aptose management team will be hosting investor meetings during both events.

Details of the events are as follows:

Event:     H.C. Wainwright BIOCONNECT Virtual Conference
Date:     January 10-13, 2022
Time:     Presentations available starting at 7:00 a.m., ET on January 10, 2022
Webcast:     Accessible for registered conference attendees via the conference’s virtual platform.
       
Event:     11th Annual LifeSci Partners Corporate Access Event
Date:     January 5-7, 2022
1×1 Meeting
Requests:
    Register and submit 1×1 meeting requests here.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML), and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.  

For further information, please contact:

Aptose Biosciences Inc.     LifeSci Advisors, LLC
Susan Pietropaolo     Dan Ferry, Managing Director
Investor Relations     617-430-7576 
201-923-2049     Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com      

Staff

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

22 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

22 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

22 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

22 hours ago